Neisseria Meningitidis Patents (Class 424/250.1)
-
Publication number: 20100285069Abstract: A dual formulation for vaccines against Neisseria meningitidis serogroup B (‘Men-B’) comprises (i) an oil-in-water emulsion adjuvant and (ii) a Men-B immunogenic component in lyophilised form. The lyophilised Men-B antigens can be reconstituted into liquid adjuvanted form at the time of use ready for administration to a patient. This formulation has been found to give excellent result in terms of both stability and immunogenicity. The lyophilised component can also include one or more conjugated saccharides from N. meningitidis in serogroups A, C, W135 and/or Y.Type: ApplicationFiled: October 17, 2008Publication date: November 11, 2010Inventors: Mario Contorni, Jina Kazzaz, Derek O'Hagan, Manmohan Singh, Mildred Ugozzoli
-
Publication number: 20100272725Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.Type: ApplicationFiled: December 18, 2009Publication date: October 28, 2010Applicant: Novartis Vaccines and Diagnostics Srl.Inventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
-
Patent number: 7820185Abstract: An OMV preparation comprises OMVs having a sufficiently positive or negative surface charge to substantially prevent aggregation.Type: GrantFiled: July 18, 2005Date of Patent: October 26, 2010Assignee: Health Protection AgencyInventors: Andrew R. Gorringe, Phillip Vincent, Denise Halliwell, Karen M. Reddin
-
Patent number: 7807181Abstract: Provided herein are mutant strains of Neisseria meningitidis which produce Kdo-free lipid A as well as the Kdo-free lipid A molecules and immunogenic compositions containing such Kdo-free lipid A molecules from a Neisseria strain containing a genetically stable mutation which inactivates a gene selected from the group consisting of genes encoding arabinose-5-phosphate isomerase, CMP-Kdo synthetase and CMP-Kdo transferase. N. meningitidis NMB206 is a specifically exemplified strain which harbors a stable insertion mutation in the gene (kpsF) encoding A5P isomerase; strain NMB-249 is a specifically exemplified strain with a stable insertion mutation in the gene (kdtA) encoding CMP-Kdo synthetase, and strain NMB259 is specifically exemplified strain with a stable insertion mutation in the gene (kdsB) encoding CMP-Kdo transferase. Also provided by the present invention are methods for the production of Lipid A flee of 3-keto-3-deoxyoctanoic acid using these genetically stable N. meningitidis mutants.Type: GrantFiled: March 20, 2003Date of Patent: October 5, 2010Assignee: Emory UniversityInventors: David S. Stephens, Yih-Ling Tzeng, Susu Zughaier, Shanta Zimmer
-
Patent number: 7803387Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: GrantFiled: February 28, 2001Date of Patent: September 28, 2010Assignee: Novartis Vaccines and Diagnostics SRLInventors: Maria Beatrice Arico, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marizia Monica Guiliani, Mariagrazia Pizza
-
Publication number: 20100239607Abstract: The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.Type: ApplicationFiled: June 1, 2010Publication date: September 23, 2010Applicant: NOVARTIS VACCINES AND DIAGNOSTICS INC.Inventors: Derek O'Hagan, Manmohan Singh
-
Patent number: 7794733Abstract: Nucleic acid and amino acid sequences of the Omp85 proteins of N. gonorrhoeae and N. meningitidis, and fragments thereof are useful in vaccine compositions, therapeutic compositions and diagnostic compositions for use in the prevention, treatment and diagnosis of non-symptomatic gonococcal infection or symptomatic disease and non-symptomatic meningococcal infection and symptomatic disease. Antibodies are developed to these proteins and also useful in the compositions and methods described herein.Type: GrantFiled: June 26, 2003Date of Patent: September 14, 2010Assignee: The University of MontanaInventors: Ralph C. Judd, D. Scott Manning
-
Patent number: 7785608Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: GrantFiled: September 2, 2003Date of Patent: August 31, 2010Assignee: Wyeth Holdings CorporationInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 7776335Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: August 17, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20100203057Abstract: The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: ApplicationFiled: February 11, 2010Publication date: August 12, 2010Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventor: Jean-Louis Ruelle
-
Publication number: 20100189737Abstract: The meningococcal haemoglobin receptor, HmbR, is used as a vaccine antigen in combination with one or more further antigens e.g. in combination with a meningococcal outer membrane vesicle, with another purified meningococcal antigen (e.g. fHBP, 287, NadA, NspA, NhhA, App, Omp85, LOS), with a conjugated meningococcal capsular saccharide, etc.Type: ApplicationFiled: December 17, 2009Publication date: July 29, 2010Inventors: Beatrice Aricò, Maria Scarselli, Rino Rappuoli
-
Publication number: 20100143418Abstract: The invention uses polypeptide antigens and/or OMVs to immunize against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W135 and Y.Type: ApplicationFiled: April 22, 2005Publication date: June 10, 2010Inventors: Mario Contorni, Marzia Giuliani, Mariagrazia Pizza
-
Publication number: 20100136043Abstract: The invention provides an immunogenic composition comprising at least one antigen in association with micropar-tides, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject.Type: ApplicationFiled: October 21, 2009Publication date: June 3, 2010Applicant: AUSTIN RESEARCH INSTITUTEInventor: Magdalena Plebanski
-
Patent number: 7704513Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.Type: GrantFiled: March 27, 2008Date of Patent: April 27, 2010Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin
-
Patent number: 7700119Abstract: An 85 kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.Type: GrantFiled: November 1, 2005Date of Patent: April 20, 2010Assignee: Novartis Vaccines and Diagnostics SRLInventors: Marzia Monica Giuliani, Mariagrazia Pizza, Rino Rappuoli, Johan Holst
-
Publication number: 20100092509Abstract: Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodifed native saccharides, derivatives of the invention are preferentially selected during conjugation to carrier proteins, and conjugates of the derivatives show improved immunogenicity compared to native polysaccharides.Type: ApplicationFiled: October 4, 2004Publication date: April 15, 2010Inventors: Paolo Costantino, Francesco Berti
-
Publication number: 20100092519Abstract: The present invention is in the field of combination therapies, including vaccine compositions, which comprise polysaccharide-protein conjugates and outer membrane vesicles (OMVs) from commensal bacteria, particularly commensal Neisseria.Type: ApplicationFiled: February 20, 2008Publication date: April 15, 2010Applicants: HEALTH PROTECTION AGENCY, SERUM INSTITUTE OF INDIA LIMITEDInventors: Andrew Richard Gorringe, Michelle Finney, Subhash V. Kapre, Akshay Goel
-
Patent number: 7691383Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.Type: GrantFiled: October 6, 2005Date of Patent: April 6, 2010Assignee: The Board of Trustees of the University of IllinoisInventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
-
Publication number: 20100055129Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.Type: ApplicationFiled: August 28, 2009Publication date: March 4, 2010Applicant: TAIGA BIOTECHNOLOGIES, INC.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Patent number: 7666988Abstract: The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: March 7, 2000Date of Patent: February 23, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Catherine Defrenne, Christine Delmelle, Jean-Louis Ruelle
-
Patent number: 7662399Abstract: The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASB047, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: July 12, 2004Date of Patent: February 16, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 7655245Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B) and from Neisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.Type: GrantFiled: June 8, 2004Date of Patent: February 2, 2010Assignee: Novartis AGInventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
-
Publication number: 20100015175Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: ApplicationFiled: July 24, 2009Publication date: January 21, 2010Applicant: Isis Innovation Ltd.Inventors: Joyce S. Plested, Michael P. Jennings, Margaret Anne Gidney, Andrew D. Cox, James C. Richards, E. Richard Moxon
-
Publication number: 20100003283Abstract: The invention provides lipid A deficient mutant Neisseria meningitidis cells, pharmaceutical compositions incorporating such cells, and methods of using such cells.Type: ApplicationFiled: October 20, 2008Publication date: January 7, 2010Inventors: Michael A. Apicella, Deborah Post
-
Publication number: 20100003280Abstract: Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.Type: ApplicationFiled: June 22, 2009Publication date: January 7, 2010Inventors: Derek O'Hagan, Nicholas Valiante
-
Patent number: 7641910Abstract: The invention provides BASB027 polypeptides and polynucleotides encoding BASB027 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: July 22, 2004Date of Patent: January 5, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Carlota Vinals y de Bassols
-
Publication number: 20090304743Abstract: The invention relates to immunogenic compositions containing CD1d ligands that induce long-term immunological memory in the absence of booster doses and/or in the absence of multiple priming doses. The invention further relates to immunogenic compositions containing CD1d ligands and antigens from influenza virus, group B streptococcus and serogroup B meningococcus.Type: ApplicationFiled: March 15, 2007Publication date: December 10, 2009Inventor: Grazia Galli
-
Patent number: 7618636Abstract: WO99/36544 discloses a large number of proteins from Neisseria Meningitidis. The present invention relates to fragments of those proteins which comprise at least one antigenic determinant. Homologous sequences and proteins comprising these fragments are also disclosed.Type: GrantFiled: July 13, 2000Date of Patent: November 17, 2009Assignee: Novartis Vaccines And Diagnostics SRLInventors: Vega Masignani, Vincenzo Scarlato, Maria Scarselli, Cesira L. Galeotti, Marirosa Mora
-
Patent number: 7604810Abstract: To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N. gonorrhoeae.Type: GrantFiled: May 2, 2007Date of Patent: October 20, 2009Assignee: Novartis Vaccines and Diagnostics SRLInventor: Rino Rappuoli
-
Publication number: 20090246224Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects.Type: ApplicationFiled: June 8, 2007Publication date: October 1, 2009Inventors: Nathalie Devos, Christiane Feron, Jan Pollman, Vincent Weynants
-
Patent number: 7585510Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: October 2, 2000Date of Patent: September 8, 2009Assignee: ISIS Innovation LimitedInventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
-
Publication number: 20090214537Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: ApplicationFiled: May 12, 2006Publication date: August 27, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Marco Soriani, Isabella Santi
-
Publication number: 20090208533Abstract: Provided are methods for recombinant production of an O-acetyltransferase and methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using the recombinant O-acetyltransferase, and immunogenic compositions comprising the acetylated capsular polysaccharide.Type: ApplicationFiled: November 20, 2007Publication date: August 20, 2009Applicants: University of Georgia Research Foundation, Inc., Emory UniversityInventors: David S. Stephens, Seshu K. Gudlavalleti, Yih-Ling Tzeng, Anup K. Datta, Russell W. Carlson
-
Patent number: 7576176Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: GrantFiled: April 30, 1999Date of Patent: August 18, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
-
Publication number: 20090202593Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.Type: ApplicationFiled: June 16, 2008Publication date: August 13, 2009Applicant: WyethInventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
-
Patent number: 7556810Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: GrantFiled: July 19, 2006Date of Patent: July 7, 2009Assignee: The Board of Trustees of the University of IlinoisInventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Publication number: 20090148469Abstract: A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from N. meningitidis.Type: ApplicationFiled: October 20, 2008Publication date: June 11, 2009Inventors: Andrew Robinson, Andrew Richard Gorringe, Michael John Hudson, Karen Margaret Reddin
-
Publication number: 20090136547Abstract: Capsular saccharides are typically anionic. In the invention, however, cationic groups are introduced, such that the modified saccharide has a repeating unit which includes both cationic and anionic groups. These cationic and anionic groups can be balanced to give a zwitterionic repeating unit. These modifications can convert a saccharide that is normally a T-independent antigen into one that can activate T cells without requiring conjugation to a carrier. Typically, the invention modifies an anionic bacterial capsular saccharide antigen by converting a neutral group in the saccharide into a cationic group e.g. to change —NHAc to —NH3+.Type: ApplicationFiled: August 24, 2006Publication date: May 28, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: John Telford, Francesco Berti, Andreas Wack
-
Patent number: 7534444Abstract: Molecular mimetics of a surface-exposed epitope on loop 4 of PorA of Neisseria meningitidis serogroup B (MenB) P1.2 serosubtype and antibodies produced against the same are disclosed. Compositions containing such molecular mimetics or the antibodies thereto can be used to prevent MenB disease, as well as for diagnosis of MenB infection.Type: GrantFiled: April 11, 2002Date of Patent: May 19, 2009Assignee: Novattis Vaccines and Diagnostics, Inc.Inventors: Dan M. Granoff, Gregory Moe, Rino Rappuoli
-
Publication number: 20090123499Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and more effective for use in human subjects.Type: ApplicationFiled: June 8, 2007Publication date: May 14, 2009Inventors: Nathalie Devos, Christiane Feron, Jan Poolman, Vincent Weynants
-
Publication number: 20090117148Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.Type: ApplicationFiled: January 9, 2009Publication date: May 7, 2009Applicant: Corporate Intellectual Property R338Inventor: Paolo Costantino
-
Patent number: 7524509Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: GrantFiled: March 11, 2002Date of Patent: April 28, 2009Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Patent number: 7521549Abstract: The invention provides BASB041, 43, 44 and 48 polypeptides and polynucleotides encoding BASB041, 43, 44 and 48 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: January 9, 2004Date of Patent: April 21, 2009Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Jean-Louis Ruelle, Vincent George Christian Louis Verlant
-
Publication number: 20090068229Abstract: Novel proteins that constitute modified forms of a Neisseria meningitidis surface antigen and encoding nucleic acids are provided. The modified surface proteins are characterized by having deletions of non-conserved amino acids, and thereby being capable of eliciting cross-protective immune responses against Neisseria meningitidis. The invention extends to the use of the modified surface antigens in diagnostics, in therapeutic and prophylactic vaccines and in the design and/or screening of medicaments. The modified surface antigens are particularly useful in vaccines which effectively immunize against a broader spectrum of N. meningitidis strains than would be expected from a corresponding wild-type surface antigen.Type: ApplicationFiled: October 31, 2007Publication date: March 12, 2009Applicant: THE UNIVERSITY OF QUEENSLANDInventors: Ian Richard Anselm Peak, Michael Paul Jennings
-
Publication number: 20090053237Abstract: The present invention is drawn to a penicillin-binding protein expressed by Neisseria meningitidis, or a fragment, or a variant, or a variant fragment thereof, or nucleic acids encoding them, or antibodies or antibody fragments directed against them, as medicaments or in pharmaceutical compositions. The invention is also directed to the use of penicillin-binding proteins expressed by Neisseria meningitidis, or nucleic acids encoding them, or antibodies directed against them for the prophylactic and/or therapeutic immunotherapy of mammals, preferably human beings, against infection by Neisseria meningitidis and/or by a bacterial strain expressing a variant of a Neisseria meningitidis penicillin-binding protein.Type: ApplicationFiled: May 22, 2006Publication date: February 26, 2009Applicant: INSTITUT PASTEURInventors: Maria Leticia Zarantonelli, Aude Antignac, Jean-Michel Alonso, Muhamed-Kheir Taha, Faridabano Nato
-
Patent number: 7491517Abstract: Methods for producing quadrivalent meningococcal meningitis polysaccharide and conjugate vaccines for serotypes A, C, Y and W-135 disclosed. Neisseria meningitidis fastidious medium was designed to maximize the yield of capsular polysaccharides and generate minimal cellular biomass and endotoxin in a short duration of fermentation. The crude polysaccharides are isolated, purified, and mechanically depolymerized by sonication. These purified polysaccharides were found in human clinical trials to be safe and immunogenic against meningococcal disease caused by N. meningitidis A, C, Y and W-135 serogroups in sub-Saharan Africa. In the preferred embodiment, the polysaccharides are conjugated to carrier proteins of diphtheria or tetanus toxiod to an average molecular size of 5100 to 9900 Daltons and provide broad spectrum protection to humans of all ages. Accelerated polysaccharide production and the efficacy of the resulting vaccine are demonstrated.Type: GrantFiled: February 28, 2007Date of Patent: February 17, 2009Inventor: Jeeri R Reddy
-
Publication number: 20090041807Abstract: An OMV preparation comprises OMVs having a sufficiently positive or negative surface charge to substantially prevent aggregation.Type: ApplicationFiled: July 18, 2005Publication date: February 12, 2009Inventors: Andrew R. Gorringe, Phillip Vincent, Denise Halliwell, Karen M. Reddin
-
Patent number: 7485304Abstract: A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.Type: GrantFiled: April 6, 2006Date of Patent: February 3, 2009Assignee: Novartis Vaccines and Diagnostics SRLInventor: Rino Rappuoli
-
Publication number: 20090017073Abstract: A method for modulating Nod1 activity wherein said method comprises the steps of providing cells expressing a functional Nod1: and bringing said cells into contact with a molecule related to compositions comprising a molecule related to MTP and use of a molecule related to MTP for modulating inflammation and/or apoptosis.Type: ApplicationFiled: June 5, 2008Publication date: January 15, 2009Inventors: Philippe Sansonetti, Stephen Girardin, Dana Philpott, Ivo Boneca
-
Publication number: 20090010944Abstract: The invention relates to methods of producing, and compositions comprising, an isolated alpha (2?8) or (2?9) oligosialic acid derivative bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exoneuraminidase. A representative production method involves: (i) treating an alpha (2?8) or (2?9) oligosialic acid precursor having a reducing end and a non-reducing end with sodium borohydride under conditions for de-N-acetylating the non-reducing end; and (ii) isolating alpha (2?8) or (2?9) oligosialic acid derivative having one or more de-N-acetylated residues and a non-reducing end that is resistant to degradation by exoneuraminidase. Isolated alpha (2?8) or (2?9) oligosialic acid derivatives that comprise a non-reducing end de-N-acetyl residue are provided, as well as antibodies specific for the derivatives, compositions comprising the derivatives, kits, and methods of use including protection against and detection of E. coli K1 and N.Type: ApplicationFiled: July 3, 2008Publication date: January 8, 2009Inventors: Gregory R. Moe, Brent T. Hagen